Completed PHASE3 INTERVENTIONAL NCT00048945

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Sponsor: Hoffmann-La Roche

Interventions PEGASYS

Updated 8 times since 2017 Last updated: Feb 16, 2017 Started: Jan 31, 2002 Primary completion: Oct 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis B and is currently completed. Hoffmann-La Roche leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Bangkok, Thailand , Basel, Switzerland , Beijing, China , Berlin, Germany , Bialystok, Poland , Bochum, Germany , Boston, United States , Bydgoszcz, Poland and 47 more locations